Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
25.59
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
5
Next >
Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer
August 11, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
August 05, 2022
Upgrades
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
July 20, 2022
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.
Via
Benzinga
Deciphera Raises $150M Via Equity Offering
April 27, 2022
Via
Benzinga
Short Volatility Alert: Deciphera Pharmaceuticals, Inc.
June 13, 2022
On Friday, shares of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) experienced volatile short activity. After the activity, the stock price moved down -5.45% to $11.27. The overall sentiment for DCPH...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Preview: Deciphera Pharmaceuticals's Earnings
May 03, 2022
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Deciphera Pharmaceuticals Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
May 03, 2022
Deciphera Pharmaceuticals (NASDAQ:DCPH) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
April 26, 2022
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...
Via
Benzinga
Deciphera's DCC-3116/KRAS Inhibitor Combo Shows Deeper, Longer Tumor Regressions In Preclinical Studies
April 13, 2022
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH)
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 06, 2022
Gainers
Via
Benzinga
Deciphera Pharmaceuticals Inc. Climbs To Annual-High Share Price
April 06, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
March 28, 2022
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 09, 2022
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...
Via
Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
February 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
Earnings Scheduled For February 8, 2022
February 08, 2022
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.
Via
Benzinga
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...
Via
Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...
Via
Benzinga
Deciphera: Why There Won’t Be a Quick Recovery
December 09, 2021
It will take awhile for DCPH stock to recover after major clinical setback
Via
InvestorPlace
691 Stocks Are Down Over 50% This Year
December 05, 2021
It may be hard to believe because the stock market has been in such an uptrend this year, but there are some interesting statistics for stock performance year-to-date.
Via
Talk Markets
Why Deciphera Pharmaceuticals Shot 12% Higher Today
November 30, 2021
The company announced a comprehensive restructuring program.
Via
The Motley Fool
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
November 30, 2021
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.
Via
InvestorPlace
Deciphera Pharma Stock Rises After Announcing Corporate Restructuring
November 30, 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors...
Via
Benzinga
Don’t Bet on a Deciphera Stock Comeback
November 30, 2021
Investors weren't wrong in dumping DCPH stock after terrible top-line results for the biotech company's flagship candidate. Avoid for now.
Via
InvestorPlace
Deciphera's Qinlock Approved In Europe For Gastric Cancer
November 22, 2021
The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal...
Via
Benzinga
Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals
November 16, 2021
Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.
Via
InvestorPlace
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.